Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...
Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...
Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...
More than a week ahead of its priority PDUFA date, the U.S. FDA has greenlit the first dual HER2-targeted bispecific antibody specifically for previously treated, unresectable or metastatic ...
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...
and a diet high in salt and animal protein for kidney stones. If they are not treated on time then they can lead to complications. There can be infections or blockages in the urinary or biliary tract.
as monotherapy for previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval makes the bispecific antibody the first HER2-targeted treatment to carry ...